Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5601
iShares US Tech Independence Focused ETF
IETC
$699M
| $330K | ﹤0.01% |
3,078
+269
| +10% | +$28K |
2023 Q3
11 quarters
|
|
5602
BondBloxx High Yield Income ETF
HYSA
$107M
| $330K | ﹤0.01% |
22,054
| – | – |
2023 Q3
11 quarters
|
|
5603
DiaMedica Therapeutics
DMAC
$413M
| $330K | ﹤0.01% |
46,874
-58,546
| -56% | -$360K |
2020 Q2
24 quarters
|
|
5604
FT Vest US Equity Buffer ETF July
FJUL
$1.4B
| $330K | ﹤0.01% |
5,541
| – | – |
2021 Q3
19 quarters
|
|
5605
ALX Oncology
ALXO
$124M
| $327K | ﹤0.01% |
157,873
+59,038
| +60% | +$106K |
2020 Q3
23 quarters
|
|
5606
Rithm Property Trust
RPT
$82.7M
| $325K | ﹤0.01% |
22,546
-3,943
| -15% | -$56.9K |
2015 Q1
45 quarters
|
|
5607
KULR Technology Group
KULR
$92.1M
| $324K | ﹤0.01% |
85,125
+18,697
| +28% | +$62.3K |
2024 Q4
6 quarters
|
|
5608
KraneShares China Technology & Semiconductor STAR 50 Index ETF
KSTR
$338M
| $324K | ﹤0.01% |
+10,000
| New | +$238K |
2026 Q2
0 quarters
|
|
5609
Coherus Oncology
CHRS
$162M
| $323K | ﹤0.01% |
230,748
+33,237
| +17% | +$54.3K |
2014 Q4
46 quarters
|
|
5610
Invesco Bloomberg Analyst Rating Improvers ETF
UPGD
$108M
| $323K | ﹤0.01% |
3,940
| – | – |
2013 Q2
52 quarters
|
|
5611
Bassett Furniture
BSET
$186M
| $321K | ﹤0.01% |
18,127
-1,565
| -8% | -$23.2K |
2013 Q2
52 quarters
|
|
5612
Cardiff Oncology
CRDF
$75.7M
| $320K | ﹤0.01% |
246,095
+189,789
| +337% | +$301K |
2013 Q3
51 quarters
|
|
5613
Lexicon Pharmaceuticals
LXRX
$712M
| $319K | ﹤0.01% |
132,902
-86,960
| -40% | -$169K |
2013 Q2
52 quarters
|
|
5614
Kenon Holdings
KEN
$3.22B
| $319K | ﹤0.01% |
4,767
+1,114
| +30% | +$91.2K |
2019 Q1
29 quarters
|
|
5615
Carlsmed
CARL
$378M
| $319K | ﹤0.01% |
30,699
+19,273
| +169% | +$203K |
2025 Q3
3 quarters
|
|
5616
VSE Corp Tangible Equity Units
VSECU
$1.23B
| $319K | ﹤0.01% |
5,525
-475
| -8% | -$24.1K |
2026 Q1
1 quarter
|
|
5617
Crescent Biopharma
CBIO
$467M
| $319K | ﹤0.01% |
17,698
-879
| -5% | -$17.2K |
2015 Q1
45 quarters
|
|
5618
SANUWAVE Health Inc
SNWV
$44.2M
| $316K | ﹤0.01% |
31,619
+25,826
| +446% | +$400K |
2025 Q1
5 quarters
|
|
5619
Main Sector Rotation ETF
SECT
$2.89B
| $316K | ﹤0.01% |
4,387
+3,079
| +235% | +$210K |
2021 Q4
18 quarters
|
|
5620
Vince Holding Corp
VNCE
$154M
| $315K | ﹤0.01% |
44,105
+36,870
| +510% | +$170K |
2013 Q4
50 quarters
|
|
5621
Direxion Daily INTC Bull 2X ETF
LINT
$65.8M
| $315K | ﹤0.01% |
+1,230
| New | +$193K |
2026 Q2
0 quarters
|
|
5622
Organigram Holdings
OGI
$130M
| $314K | ﹤0.01% |
308,108
-56,076
| -15% | -$68.5K |
2019 Q2
28 quarters
|
|
5623
AC Immune
ACIU
$239M
| $314K | ﹤0.01% |
131,815
+42,562
| +48% | +$117K |
2017 Q4
34 quarters
|
|
5624
Ideal Power
IPWR
$51.9M
| $313K | ﹤0.01% |
58,396
+37,336
| +177% | +$190K |
2014 Q3
47 quarters
|
|
5625
Meridian Holdings Inc
MRDN
$139M
| $313K | ﹤0.01% |
22,480
+18,079
| +411% | +$189K |
2024 Q2
8 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.